Ervin Fodor honoured with the 2019 AstraZeneca Award

Ervin Fodor honoured with the 2019 AstraZeneca Award

Ervin Fodor has received the 2019 AstraZeneca award following a recent meeting of the awarding body, The Biochemical Society, in Spring 2018. The award, supported by the multinational biopharmaceutical company AstraZeneca, is made every three years in recognition of outstanding work that contributes to the development of a new reagent or method in the field of biomedical science.

Fodor’s research focuses on the molecular mechanisms of influenza virus replication, virus-host interactions, and host responses to viral infection. His research group played a pivotal role in uncovering the high-resolution structure of the influenza virus RNA-dependent RNA polymerase, and deciphering how influenza virus hijacks the host transcriptional machinery for the transcription of its own genes. A reverse genetics system for influenza virus, developed by Fodor and colleagues in the late 90s, is used for the preparation of a live attenuated influenza virus vaccine for the UK National Childhood Flu Immunisation Programme.

Fodor expressed his “surprise” and “delight ” at  receiving the AstraZeneca Award. He said: “It is a great honour to join the list of previous eminent winners of this award. I accept this award on behalf of all past and present members of my group, and my collaborators. This would have not been possible without their hard work and dedication. I am also indebted to the Medical Research Council for generously supporting our research for many years.”

Ervin Fodor has been invited to give an award lecture at a Biochemical Society meeting scheduled for 2019. He will also receive a prize fund of £2000.

For more information on the Fodor lab research work visit: https://fodor.path.ox.ac.uk

For previous list of AstraZeneca awardees, visit: https://www.biochemistry.org/Awards/AstraZenecaAward.aspx

Written by Sonia Muliyil (@Muliyilsonia)

Thursday, April 5, 2018 - 09